000127450 001__ 127450
000127450 005__ 20240228140928.0
000127450 0247_ $$2doi$$a10.1007/s11764-015-0437-z
000127450 0247_ $$2pmid$$apmid:25711667
000127450 0247_ $$2ISSN$$a1932-2259
000127450 0247_ $$2ISSN$$a1932-2267
000127450 0247_ $$2altmetric$$aaltmetric:3735759
000127450 037__ $$aDKFZ-2017-03473
000127450 041__ $$aeng
000127450 082__ $$a610
000127450 1001_ $$0P:(DE-He78)9fcfe1306c0e35afdc4503b65f496834$$aScharhag-Rosenberger, Friederike$$b0$$eFirst author$$udkfz
000127450 245__ $$aExercise training intensity prescription in breast cancer survivors: validity of current practice and specific recommendations.
000127450 260__ $$aNew York, NY [u.a.]$$bSpringer$$c2015
000127450 3367_ $$2DRIVER$$aarticle
000127450 3367_ $$2DataCite$$aOutput Types/Journal article
000127450 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524135269_24147
000127450 3367_ $$2BibTeX$$aARTICLE
000127450 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127450 3367_ $$00$$2EndNote$$aJournal Article
000127450 520__ $$aCancer survivors are recommended to perform 150 min/week of moderate or 75 min/week of vigorous aerobic exercise, but it remains unclear how moderate and vigorous intensities can be prescribed. Therefore, it was investigated whether and how intensity prescriptions for healthy adults by the American College of Sports Medicine (ACSM) need to be adapted for breast cancer survivors.Fifty-two breast cancer survivors (stage 0-III, age 52 ± 9 years, BMI 25.4 ± 3.5 kg/m2) performed cardiopulmonary exercise tests at the end of primary therapy. Intensity classes defined as percentages of maximal heart rate (HRmax), heart rate reserve (HRR), and maximal oxygen uptake (VO2max) were compared to the ACSM's intensity classes using oxygen uptake reserve as reference.The prescriptions for moderate and vigorous exercise intensities were significantly different between breast cancer survivors and healthy adults when using VO2max (moderate 50-66 vs. 46-63 and vigorous 67-91 vs. 64-90% VO2max) or HRR (moderate 26-50 vs. 40-59 and vigorous 51-88 vs. 60-89 % HRR), but not when using HRmax (moderate 65-76 vs. 64-76 and vigorous 77-94 vs. 77-95% HRmax).In breast cancer survivors, intensity prescriptions for healthy adults result in considerably too intense training if HRR is used as guiding factor. Prescriptions using VO2max result in a slightly too low exercise intensity, whereas recommendations in percentages of HRmax appear valid.Cancer survivors should not uncritically adopt exercise intensity prescriptions for healthy adults. Specific prescriptions for the studied population are provided.
000127450 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000127450 588__ $$aDataset connected to CrossRef, PubMed,
000127450 7001_ $$0P:(DE-HGF)0$$aKuehl, Rea$$b1
000127450 7001_ $$0P:(DE-HGF)0$$aKlassen, Oliver$$b2
000127450 7001_ $$aSchommer, Kai$$b3
000127450 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b4$$udkfz
000127450 7001_ $$aUlrich, Cornelia M$$b5
000127450 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b6$$udkfz
000127450 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b7$$eLast author$$udkfz
000127450 773__ $$0PERI:(DE-600)2388888-X$$a10.1007/s11764-015-0437-z$$gVol. 9, no. 4, p. 612 - 619$$n4$$p612 - 619$$tJournal of cancer survivorship$$v9$$x1932-2267$$y2015
000127450 909CO $$ooai:inrepo02.dkfz.de:127450$$pVDB
000127450 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9fcfe1306c0e35afdc4503b65f496834$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127450 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127450 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127450 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000127450 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127450 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000127450 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000127450 9141_ $$y2015
000127450 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127450 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127450 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER SURVIV : 2015
000127450 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127450 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127450 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127450 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index
000127450 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences
000127450 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127450 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000127450 9201_ $$0I:(DE-He78)G111-20160331$$kG111$$lBewegung, Sport und Krebs$$x0
000127450 980__ $$ajournal
000127450 980__ $$aVDB
000127450 980__ $$aI:(DE-He78)G111-20160331
000127450 980__ $$aUNRESTRICTED